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Objectives: This study aimed to provide a comprehensive overview of cost indicators and outcome measures used to measure
financial burden in families of children with life-limiting conditions.
Methods: A scoping review methodology was used to map the existing literature and provide an overview of available cost
indicators and outcome measures. Key medical, economic, and scientific databases were systematically searched to identify
relevant articles published in 2000 or later.
Results: The database search yielded 7194 records, including 30 articles eligible for final inclusion. Retrieved cost indicators
and outcome measures fell into 3 broad categories: direct costs, indirect costs, and financial support. No study compre-
hensively assessed all 3 categories. Cost indicators used to measure direct costs were grouped into 5 medical and 11
nonmedical out-of-pocket expenses categories, of which 5 were commonly assessed (ie, treatment and diagnostics, travel and
transport, accommodation, food, childcare and home help). Half of the reviewed studies included assessments of indirect
costs, most commonly estimating work-related income loss by evaluating employment disruptions. Assessments of
opportunity costs arising from informal caregiving and of financial support were rarely included.
Conclusions: Current estimates of the financial burden faced by families of children with life-limiting conditions are
inconsistent and often incomplete, likely resulting in severe underestimations of the costs these families incur. We hope
that the framework presented in this article will contribute to a more comprehensive assessment of illness-related
financial burden and help guide future policies in this area.
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Suffering from life-limiting conditions (LLCs) is a traumatic
experience not only for the directly affected children but for their
entire families.1 Globally, the number of children living with LLCs
has increased rapidly over the last 2 decades. In Queensland,
Australia, estimates indicate an increase in LLC prevalence from
35.2 to 43.2 per 10 000 population between 2011 and 2016.2 In
England, United Kingdom, prevalence increased from 26.7 to 63.2
(per 10 000) between 2001 to 2002 and 2017 to 2018.3 Although
advances in life-extending medical care and technology can
partially explain these figures,4,5 changes in medical coding
practice and recording may also have had an effect.3
According to Together for Short Lives,6 LLCs encompass 4
groups of conditions: (1) conditions for which curative treatment
may be feasible but can fail, for example, cancer or irreversible
organ failure; (2) conditions in which premature death is15 - see front matter Copyright ª 2021, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/licinevitable but in which there may be long periods of intensive
treatment, for example, Duchenne muscular dystrophy; (3)
progressive conditions without curative treatment options, for
example, severe metabolic conditions; and (4) irreversible but
nonprogressive conditions causing severe disability creating sus-
ceptibility to health complications and likelihood of premature
death, for example, cerebral palsy.
Caring for a child with an LLC is a profoundly difficult and
dramatic experience for affected families. Persistent stress, anxi-
ety, feelings of fear, and deteriorations of family life are commonly
reported.1,7,8 Symptoms of distress and anxiety can be further
compounded by financial stressors, including not only non-
reimbursed expenses for hospitalizations, medications and
equipment7 but often conflicts between employment obligations
and childcare responsibilies.8
Considerable research has examined families’ financial burden
in pediatric oncology. Systematic reviews of the cost of childhoodHealth Economics and Outcomes Research. Published by Elsevier Inc. This is an
enses/by-nc-nd/4.0/).
1378 VALUE IN HEALTH SEPTEMBER 2021cancer from a family perspective have identified a large variety of
adverse economic consequences,9–11 including substantial out-of-
pocket expenses10 and parental employment disruptions and
income loss.9 Nevertheless, because few studies have reported
illness-related costs in a comprehensive and comparable manner,
it is difficult to exploit published data for research and policy
making.9–11
Measuring Financial Burden
Cost-of-illness studies provide a framework for measuring the
financial burden of disease to families.12,13 These studies tradi-
tionally distinguish between direct and indirect costs and, if
applicable, also adjust for financial support received. Direct costs,
that is, out-of-pocket expenses directly incurred by affected fam-
ilies, are commonly divided into medical and nonmedical
expenses.12 Out-of-pocket medical expenses, that is, those directly
related to the consumption of healthcare resources, include co-
payments, deductibles, co-insurances, and all direct charges not
covered by formal payers. Out-of-pocket expenses not related to
the consumption of healthcare resources, but nevertheless
necessitated directly by health conditions, such as travel costs to
and from hospitals, are classified as nonmedical. Indirect costs
include changes in productivity and work, for example, when
parental caregiving responsibilities require changes in employ-
ment status (leaving or reducing work) that cut income.12,13 For
informal caregivers, work-related income loss and opportunity
costs owing to forgone earnings are common indirect costs.13
Whether costs are direct or indirect or medical or nonmedical,
financial support from both governmental and nongovernmental
entities may be available to mitigate the resulting financial
burden.
Although cost-of-illness study designs provide a generic
framework for measuring financial burden, distinct sets of estab-
lished indicators and cost measures for measuring direct and in-
direct costs are largely lacking. In addition, previous reviews found
substantial inconsistencies in these studies’ definitions and ter-
minology and a general lack of standardization of relevant
outcome measures.9–11 For example, indicators and outcome
measures differed depending on whether studies used micro-
costing or general estimates.11 Problematically, the general lack
of consensus on cost indicators and outcome measure classifica-
tions causes inconsistencies in reporting limiting the extent to
which findings can be compared across studies.9,10 Such reporting
differences seem particularly large regarding financial support
received by families.9
The purpose of this scoping review was to provide a compre-
hensive overview of existing cost indicators and outcome
measures used to measure financial burden in families of children
with LLCs. To increase standardization and consistency, we also
aimed to categorize retrieved cost indicators and outcome
measures, along with providing detailed information on how they
were assessed. We expect that reducing inconsistencies in this
way will facilitate the development and implementation of
effective healthcare policies supporting affected families by
reducing adverse financial consequences.Methods
Study Design
This scoping review was conducted following the 5-step
methodological framework (ie, research question identification,
study identification, study selection, charting of data, and
collating, summarizing, and reporting results) proposed by Arkseyand O’Malley14 and developed by Levac et al.15 By including
studies of diverse designs and methodologies, scoping reviews can
provide a broad descriptive overview of the nature and charac-
teristics of available research and its findings.14,15 Therefore, they
provide an ideal framework for mapping, consolidating, and
disseminating evidence concerning cost indicators and outcome
measures used to measure a topic as complex as financial burden.
Search Strategy
For advice on designing our database search strategies, we
consulted an experienced librarian. The resulting search strate-
gies, including search terms and subject headings, are available as
Supplemental Materials. The Boolean operators AND and OR were
used to combine search terms and subject headings. We searched
titles and abstracts in the MEDLINE and CINAHL medical data-
bases, the EconLit economic database, and the Scopus science
database. Subject headings were added when searching MEDLINE,
CINAHL, and EconLit using the EBSCOhost research platform. Gray
literature was located using Google Scholar web searches. The
database search was performed first between May 29 and June 3,
2019, and then again on March 18, 2020, to find any newly
published articles.
Eligibility Criteria
Published articles were included if they reported on financial
burden among families of children with LLCs, including any
identifiable direct and indirect illness-related costs. To account for
recent advances in research methodology and changes in health
policy, we included all relevant studies published in 2000 or later.
No language restrictions were applied. Studies where parents of
children with LLCs were not the main focus (eg, those including
nonlife-limiting chronic illnesses such as asthma, allergies, or
migraines) were excluded. Studies were also excluded if they
assessed perceived rather than economically quantified burden.
Study Selection
Search results were stored and managed via EndNoteX9TM
reference software (Clarivate Analytics, London, United Kingdom).
After removing duplicates, 2 study team members (T.M. or A.K.G.
and S.M.) independently screened titles and abstracts and then
independently assessed the full text of those retained. At each
selection stage, any disagreements were resolved via discussions
involving a third team member (K.Z.).
Data Charting and Reporting
We extracted data regarding study characteristics, including
study design, participants, assessed outcomes, recall periods, and
data collection mode and authors’ names, year of publication, and
country of origin (Table 1). Cost indicators and outcome measures
were grouped into 3 categories: direct costs, indirect costs, and
financial support. Where studies reported direct costs, data were
further grouped into out-of-pocket medical and nonmedical
expenses categories (Table 2). Data on indirect costs (income loss,
opportunity costs) and financial support are provided respectively
in Tables 3 and 4. All indicators and their categorizations were
discussed within the study team.
Because this study’s purpose was to provide structured evi-
dence regarding previously reported cost indicators and outcome
measures, included studies’ quality was not assessed. As a
reporting guideline, we followed the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) extension for
scoping reviews (PRISMA-ScR).16
Table 1. Characteristics of included studies.
Author(s),
Country
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Study Selection
Our database search yielded 7194 records. After removal of
duplicates, screening of titles and abstracts, full-text assessments,
and a gray literature search, 30 articles reporting on 28 studiesTable 2. Categorized out-of-pocket expenses indicators.
Out-of-pocket medical expenses
Treatment and diagnostics 11/16 (69%)*
- Pharmacotherapy23,27,28,31,35-38,40,42,43 (prescription and nonpre-
scription medications)
- Therapeutic and surgical procedures32 (eg, surgery, radiation,
transfusions)
- Special treatments and supportive therapy32,36-38,42,43 (eg, chiro-
practor, massages, physiotherapy, rehabilitation services)
- Complementary and alternative therapy27,37,38,42 (eg, homeopathy)
- Investigations and diagnostic tests31,32,36,42 (eg, radiological in-
vestigations, laboratory tests)
In- and outpatient charges and fees 7/16 (44%)*
- Inpatient payments and hospital charges23,31
- Public hospital bed charges43
- Outpatient charges and payments23,43
- Doctor and specialist fees28,40,43
- Consultation fees36,42
- Ward entrance fees42
Equipment and assistive technology 3/16 (19%)*
- Seating and standing equipment, specialized tables29
- Specialized car, car modifications29,37,38
- Mobility devices29,36-38 (eg, crutches, wheelchair)
- Support equipment29,37,38 (eg, eyewear, splints, monitoring de-
vices, ventilator)
- Communication devices29 (eg, displays, software)
- Equipment for eating and drinking29 (eg, adapted cups, spoons,
bottles, tubes)
- Equipment for toileting, bathing, and dressing29
- Equipment for sleeping29 (eg, special mattress, body position
support, height adjusted bed)
Medical aids, dressings, and disposables 3/16 (19%)*
- Medical aids and dressings28,42
- Medical disposables (eg, gloves, syringes)31
Other
- Medical fees and costs for other family members or caregivers as a
result of a child’s illness36-38
Total expenses 4/16 (25%)*
- Total out-of-pocket medical expenses above and beyond health
insurance premiums or reimbursed healthcare costs18-21
TV indicates television.
*Number of studies measuring out-of-pocket medical expenses reporting at least on
†Number of studies measuring out-of-pocket nonmedical expenses reporting at leastqualified for inclusion. Figure 1 illustrates the selection process
using a PRISMA flow chart.
Characteristics of Included Studies
Of the 28 studies covered by the 30 included articles, 9 were
conducted in the United States,17–25 with a tenth cross-nationalOut-of-pocket nonmedical expenses
Travel and transport 15/16 (94%)†
- Travel and transport17,22,27,28,30-32,35-40,42,43,46 (eg, airfare, gasoline,
vehicle maintenance and registration, taxi, parking, public trans-
port, roadway tolls, car rental, mileage)
Accommodation 11/16 (69%)†
- Accommodation17,22,28,30-32,37-39,42,43,46 (eg, lodging, room or bed
rent, rented house, hotel or motel, hospitality house provided by
volunteer families, hospital sponsored housing)
Food 11/16 (69%)†
- Additional food17,27,30-32,36-39,42,43,46 (eg, eating out, snacks, special
diet foods during home stay)
Childcare and home help 10/16 (63%)†
- Childcare17,27-29,36-38,43,46
- Home or domestic help17,28,37-39,42,43,46
Communication, internet and cable TV 8/16 (50%)†
- Communication28,30,31,37-40,43,46 (frequently recorded: mail, mobile
phone, landline costs)
- Internet and cable TV39
Clothing 5/16 (31%)†
- Clothing bought because of the child’s condition28,31,37,38,43,46
Gifts, treats, and toys 4/16 (25%)†
- Gifts or treats for child or other members of family37,38,43,46
- Toys or recreational opportunities29
Daily necessities and hygiene products 4/16 (25%)†
- Elements for personal and household hygiene39
- Incidental expenses, daily necessities, supplies (eg, batteries,
toiletries)17,37,38,42
Utilities 2/16 (13%)†
- Electricity,39,43 gas,39 water39
Relocation and home modifications 2/16 (13%)†
- Moving,37,38 renovations,37,38 home modifications29
Other
- Special education28,42
- Attention to visitors39
- School and extracurricular activities38
- Pet care38
- Funeral expenses43
e indicator in the respective category.
one indicator in the respective category.
Table 3. Categorized indirect cost measures.
Income loss Opportunity costs
Self-report income data 11/15 (73%)*
- Estimation of income loss by valuing illness-related work
disruptions,17,24-28,30,37,40,42 for example:
- Cutting back on work hours and commitments
- Quitting a job
- Forgone overtime
- Unpaid leave
- Closing or suspending business
- Estimation of income loss by subtracting parent-reported income
before diagnosis from parent-reported income before study
participation43
Income data from registers 3/15 (20%)*
- Estimation of income loss by analyzing income changes over
several years comparing families of children with and without a
particular health condition,33,34,44,45 including various sources of
income:
- Total income (all sources of income)
- Income from work
- Several types of benefits (eg, unemployment, sickness, childcare
related)
National Census Wage 1/15 (7%)*
- Informal caregiving time spent by both mothers and fathers valued
using US National Census Wage data37
Regional gross domestic product 1/15 (7%)*
- Informal caregiving time spent by one of the parents valued by the
per diem regional gross domestic product41
*Number of studies measuring indirect costs grouped in the respective category.
SYSTEMATIC LITERATURE REVIEW 1383study involving both Australian and US participants.26 Addition-
ally, 3 each were conducted in Australia27–29 and India,30–32 2 each
in Denmark33,34 and Nigeria,35,36 and 1 each in Canada,37,38
Colombia,39 Finland,40 Italy,41 Malaysia,42 New Zealand,43
Sweden,44,45 and the United Kingdom.46
All included studies were observational, but used various
data collection modes and recall periods. Sixteen used a
cross-sectional study design,18–22,25–30,36,39,42,43,46 collecting
data with paper-pencil questionnaires or phone-administered
surveys18–22,25,27–29,36,39,42,43,46 or combining face-to-face in-
terviews with a self-report questionnaire.26,30 Of these 16, 7
studies assessed expenses retrospectively, with a recall period of
12 months.18–21,25,27,42
Twelve studies used a longitudinal study design,17,23,24,31–35,
37,38,40,41,44,45 collecting data either via subject reports, that is,
face-to-face interviews,24 repeated questionnaire surveys,35,40 or
cost diaries,17,31,32,37,38 or by linking data from administrative
registries and medical claims databases.23,33,34,41,44,45 Interview
and questionnaire surveys were conducted for 3,35 6,24 or 15
months,40 including either 224,40 or 335 assessment time points.
Families were asked to record expenses in cost diaries for a
maximum of 12 weeks.32 Three population-based studies, 2 con-
ducted in Denmark and 1 in Sweden, linked data from various
government-administered registries,33,34,44,45 which allowed
assessment periods ranging from 844,45 to 28 years.33
Seventeen studies examined the financial impact of pediatric
cancer22,24–28,30–32,34,37–41,43–46 and 6 the costs related to cerebral
palsy.17,19,29,33,36,42 Three used samples of children suffering fromTable 4. Type and source of financial support.
Type Source
Assistance with medical expenses 4/28 (14%)*
- Assistance with treatment expenses and care
costs27,31,43,46
Assistance with nonmedical expenses 3/28 (11%)*








*Number of total studies reporting financial support within the respective category.congenital heart disease.21,23,35 Ouyang et al20 surveyed families
with children suffering from muscular dystrophy, and Thomson
et al18 examined a sample of children with complex medical
conditions, including neurological and congenital conditions and
pediatric cancer. Overall, included studies collected cost data
during different phases of illness and treatment.
Cost indicators and outcome measures assessed in the
included studies were grouped into 3 categories—direct costs
(out-of-pocket medical and nonmedical), indirect costs (income
loss and opportunity costs), and financial support. No study
comprehensively assessed all 3 categories. Eight studies assessed
both direct and indirect costs,17,27,28,30,37,38,40,42,43 with the
remainder assessing only direct18–23,29,31,32,35,36,39,46 or
indirect24–26,33,34,41,44,45 costs. Of the 15 reporting indirect costs, 14
assessed parental income loss17,24–28,30,33,34,37,40,42–45 and 2 the
opportunity costs of informal caregiving.37,41 The extent to which
out-of-pocket medical18–21,23,27–29,31,32,35–38,40,42,43 and
nonmedical17,22,27–32,35–40,42,43,46 expenses were measured varied
across studies. Financial support was assessed in 4
studies.27,31,43,46 All included studies’ characteristics are presented
in Table 1.Direct Costs: Out-of-Pocket Medical and Nonmedical
Expenses
Both out-of-pocket medical and nonmedical expenses
were reported for varying periods of time and to different extents./28 (14%)*
ort received/available from governmental sources27,31,43,46 (eg,
g allowance, carer’s allowance)
tal 3/28 (11%)*
ort received from nongovernmental sources27,31,46 (eg, charities,
s, fund-raising efforts)
Figure 1. PRISMA flow diagram of study selection. PRISMA indicates Preferred Reporting Items for Systematic Reviews and
Meta-analyses.
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1384 VALUE IN HEALTH SEPTEMBER 2021Out-of-pocket medical expenses were commonly assessed on
monthly,31,35,43 quarterly,37,38,40 or annual18–21,23,27,42 bases.
Bourke-Taylor et al29 and Cohn et al28 reported expenses since
diagnosis. In the case of out-of-pocket nonmedical expenses,
although 5 studies reported monthly figures,31,35,36,39,43 others
used shorter or longer assessment periods, ranging from daily30 to
annual27,42 or even multi-year assessments.28
Seventeen studies aggregated individual indicators to estimate
total out-of-pocket expenses.17,22,23,27–32,35–40,42,43,46 Along with
the numbers of aggregated indicators, their definitions varied. To
provide a structured overview, we grouped all extracted indicators
into 16 categories (5 out-of-pocket medical and 11 out-of-pocket
nonmedical). In addition, 4 studies estimated total out-of-pocket
medical expenses above and beyond health insurance premiums
or reimbursed healthcare costs without aggregating single
indicators.18–21 All indicators are listed in Table 2.
In terms of out-of-pocket medical expenses, the costs of
pharmacotherapy (ie, direct charges, co-payments, and de-
ductibles for prescription and nonprescription medications) were
most frequently recorded. Overall, 10 studies assessed pharma-
cotherapy costs,23,27,28,31,35–38,40,42,43 independently of context-
specific characteristics such as healthcare systems or LLCs. Other
out-of-pocket medical expenses, for example, therapeutic and
surgical procedure costs, were only assessed within specific con-
texts. For instance, in India, Ahuja et al32 measured radiation
therapy and surgery costs to families of children with cancer
because those families lacked appropriate insurance coverage. Inaddition, in Australia, Bourke-Taylor et al29 focused their study
on equipment and assistive technology expenses, because gov-
ernment funding and insurance covered only a limited range of
those, leaving some families to make up the, often, substantial
difference.
Moreover, the overall number of included indicators varied
considerably across studies. Tsimicalis et al38 assessed
expenses for 16 indicators aggregating a total of 74 breakdown
items, including specific medications (eg, antibiotics, antiemetics,
or antipyretics). In comparison, Ahuja et al32 reported expenses
for only 7 indicators. Both studies assessed out-of-pocket
expenses incurred by families of children with a diagnosis of
cancer.
Common indicators assessed regarding out-of-pocket nonmed-
ical expenses were illness-related costs for travel and transpo
rt,17,22,27,28,30–32,35–40,42,43,46 accommodation,17,22,28,30–32,37–39,42,43,46
and food.17,27,30–32,36–39,42,43,46 As with other matters, the degree
of detail in which these costs were assessed and reported
varied substantially across studies. Measuring travel expenses, Tsi-
micalis et al38 aggregated 11 breakdown items including taxi fares,
public transit, parking, and airfare. Other studies measuring out-of-
pocket nonmedical expenses provided total travel and transport
expenses only, with no itemization.17,31,46
Indirect Costs: Income Loss and Opportunity Costs
Indirect costs were assessed in 15 studies17,24–28,30,33,34,37,40–45
of which 14 recorded parental income loss.17,24–28,30,33,34,37,40,42–45
SYSTEMATIC LITERATURE REVIEW 1385The opportunity costs of informal caregiving were assessed in 2
studies.37,41 These valued informal caregiving at market wage
rates,37,41 but based their calculations on different source data.
Tsimicalis et al37 valued caregiving time according to US National
Census Wage data; Pagano et al41 used a per diem based on the
regional gross domestic product.
Measures used to quantify income loss varied. Most studies
(n = 11) used self-report data,17,24–28,30,37,40,42,43 for instance, by
using survey items with ordinal response categories24–26 or
valuing estimated work hours lost in relation to each family’s
income category.17 Dockerty et al43 estimated income loss by
subtracting each family’s Consumer Price Index (CPI)-adjusted
after-tax income before diagnosis from the CPI-adjusted after-tax
income before participating in the study. Three studies linked data
from government-administered registries to assess parental
income loss.33,34,44,45 These studies reported both changes in
income over time and income disparities between families of
children with and without specific LLCs. Nevertheless, overall,
details on income composition were rarely reported.
Outcome measures and valuation approaches are presented in
Table 3.
Financial Support
Four of our 28 reviewed studies reported the financial support
families received.27,31,43,46 Financial support was measured either
in general terms27,43,46 or specifically in relation to treatment.31
Sources of financial support included various govern-
mental27,31,43,46 and nongovernmental27,31,46 sources, such as
carer’s allowances, charity grants, support groups, or fund-raising
efforts. Table 4 provides an overview of the types and sources of
financial support provided.Discussion
We retrieved and reviewed 30 publications reporting on 28
studies measuring financial burden in families of children with
LLCs. We found that financial measures used to quantify financial
burden fit into 3 broad categories: direct costs (out-of-pocket
medical and nonmedical expenses), indirect costs (income loss,
opportunity costs), and financial support. Although most reviewed
studies covered 1 or 2 of these categories, none comprehensively
assessed all 3. Reporting gaps were particularly broad regarding
incoming financial support and the opportunity costs of informal
caregiving.
In addition, studies showed little consistency or standardiza-
tion concerning applied cost indicators and outcome measures.
This is particularly apparent in assessments of out-of-pocket
medical and nonmedical expenses, with most studies measuring
costs related to treatment (especially medication) and diagnostics,
childcare and home help, food, accommodation, and travel and
transport. Further cost categories, as presented in Table 2, were
only infrequently assessed, suggesting that, in some studies, direct
costs are underestimated. In contrast, in studies using self-report
data to estimate work-related income loss by estimating the
effects of employment disruptions, indirect costs might be
overestimated because the mitigating effects of income sub-
stitutes (eg, benefits and allowances) are insufficiently recognized.
Overall, outcome measures, methodological approaches, and the
extent to which study results were reported varied considerably
across studies. These findings support those of previous
reviews.9–11
Given that no consensus exists regarding the standardization
of financial burden measurement, with many cost categories and
outcome measures assessed inconsistently across studies, wepropose a framework for measuring direct costs (Table 5) and
general recommendations for advancing research on financial
burden and enhancing cost-of-illness studies’ methodological
consistency.
Direct Costs
Considering the pronounced variations in the extent to which
out-of-pocket expenses were assessed across studies and the fact
that we could not locate any standardized sets of established cost
indicators, our results suggest that not all direct costs were
consistently measured across studies. Previous reviews have
reported similar findings, indicating substantial inconsistencies in
identifying, measuring, and quantifying out-of-pocket ex-
penses.10,11 Nevertheless, accurate estimations of financial burden
require a comprehensive assessment of these expenses and should
aim to fully identify, measure, and evaluate the costs an illness
imposes on families.
Regarding both healthcare systems and health conditions, this
review included studies conducted in various settings and contexts.
Although our extensive analyses gave us a comprehensive overview
of a large variety of cost indicators, it also explains some of the
heterogeneity in observed out-of-pocket expenses. Although a
number of indicators (eg, prescription and nonprescription medi-
cation)may be applicable across contexts and settings, specific LLCs
and healthcare system characteristics may require context and
setting-specific indicators. For instance, because equipment and
assistive technology needs vary among LLCs and insurance
coverage varies betweenhealthcare systems, families in some areas
may face substantial direct charges for treatment and procedures
covered elsewhere by formal payers.
Regarding out-of-pocket nonmedical expenses, studies
commonly assessed childcare and home help, food, accommoda-
tion, and travel and transport expenses. These expenses have been
reported to contribute substantially to families’ financial burden.
In Canada, Tsimicalis et al38 found that travel, food, and domestic
help were the highest-ranked contributors, representing respec-
tively 56%, 18%, and 9% of the total direct costs to families of
children with cancer. Other studies reported that communication
and renovation and home modification expenses were major
drivers of financial burden.28,38 Nevertheless, across the reviewed
studies, these costs were infrequently assessed, indicating that
direct costs may be commonly underestimated.
To enable more consistent and standardized assessments of
financial burden, we used this study’s findings to generate a
framework for measuring direct costs in families of children
with LLCs (Table 5). Consisting of 16 defined cost categories, this
provides a basis for identifying, assessing, and reporting
cost indicators, many of which should be chosen in consideration
of their relevance to the study’s context and setting. Conducting
and reporting cost-of-illness studies within this standardized
framework will allow comprehensive, comparable assessments
of out-of-pocket expenses and facilitate between-study
comparisons. Methodological issues potentially arising with
this framework’s application are discussed below. Although the
proposed framework was based on direct costs incurred by
families of children with LLCs, future research should consider its
applicability to other chronic, but nonlife-limiting, conditions.
Indirect Costs
Only half of the 28 included studies provided evidence on
illness-related changes in parental income. Considering that a
recent review on the impact of childhood cancer on parents’ so-
cioeconomic situations observed a high prevalence of adverse
employment effects, particularly among mothers,9 attention to
Table 5. Framework for measuring direct costs among families of children with LLCs.





Treatment and diagnostics include all family-
incurred expenses related to procedures to
diagnose and treat a disease or injury and improve
health and health-related well-being.
- Out-of-pocket medical expenses include direct
charges, co-payments, deductibles, and co-
insurances.
- Out-of-pocket nonmedical expenses include
additional illness-related expenses above and
beyond ordinary family-incurred costs.
- Sets of indicators for measuring out-of-pocket
medical and nonmedical expenses should be
chosen in consideration of context-specific
factors (eg, healthcare system, health condition,
phases of illness, and treatment, different means
of transportation).
- Indicators should be defined in detail and their
composition clearly stated.
- Further categories and indicators may apply.
- Inconsistencies in methodological approaches
and biases associated with recall periods, data
collection modes, and aggregation issues should
be rigorously addressed (see methodological
considerations).
- Consideration should be given to the research





In- and outpatient charges and fees include all
family-incurred charges and fees for in- and





Equipment and assistive technology include all





Medical aids, dressings, and disposables include all
occasional and incidental expenses that may be
additionally incurred by families (eg, gloves, wound
dressings).
Other expenses Other expenses include potential further family-
incurred out-of-pocket medical expenses (eg,
medical costs for other family members as a result





Travel and transport include all family-incurred
illness-related travel and transport expenses.†
Accommodation Accommodation includes all family-incurred illness-
related accommodation expenses.†
Food Food includes all family-incurred illness-related




Childcare and home help include all family-incurred





Communication, internet, and cable TV include all
family-incurred illness-related expenses for
communication, internet, and cable TV above and
beyond ordinary expenses.
Clothing Clothing includes all family-incurred illness-related




Gifts, treats, and toys include all family-incurred
illness-related expenses for gifts, treats, toys, and





Daily necessities and hygiene products include all
occasional and incidental expenses that are
additionally incurred by families because of a child’s
illness (eg, batteries, soap).
Utilities Utilities include all family-incurred illness-related
expenses for utilities (eg, water, electricity, gas)




Relocation and home modifications include all
family-incurred expenses for relocating or
performing renovations and home modifications
because of a child’s illness.
Other expenses* Other expenses include all other family-incurred
illness-related out-of-pocket nonmedical expenses
not captured by other categories.
LLC indicates life-limiting condition; TV, television.
*Potential indicators, see Table 2.
†Potential cost items, see Table 2.
1386 VALUE IN HEALTH SEPTEMBER 2021employment and income effects across reviewed studies seems
rather low. One possible explanation is that no appropriate
and reliablemeasurement tools are available to assess employment
disruptions and income loss. Although most studies used
self-reported employment disruption data to estimate work-
related income loss, the reporting and valuation of these disrup-
tions were highly inconsistent. For instance, although some studies
recorded and valued specific employment disruptions (eg, numberof reduced working hours, days of unpaid leave), others used gen-
eral estimates of overall income loss (eg, by using ordinal response
categories). We also noted that most studies disregarded the po-
tential mitigating effects of financial coping strategies (eg, income
substitutions), thus likely overestimating income loses.47,48
Register-based studies more comprehensively assessed
changes in parental income. As our findings showed, these studies
not only examined income changes from a long-term perspective
SYSTEMATIC LITERATURE REVIEW 1387but also included other types of income (eg, unemployment and
sickness benefits, fund raising) potentially alleviating income loss.
Previous research indicates that income loss is most evident
shortly after diagnosis.24,40 From a long-term perspective, this
suggests that transfer payments and coping strategies may
mitigate these costs. Therefore, future studies should consider
analyzing long-term illness-related effects on parental income
beyond employment disruptions.
Regarding the opportunity costs of informal caregiving, tradi-
tional assessments involve 2 steps: measuring time spent on it
and valuing that time monetarily.49 Depending on the chosen data
collection mode, estimations may differ. In a comparison of diaries
and surveys, diaries were found to reduce the risk of
overestimations associated with long recall periods.49 Moreover,
opportunity costs may vary depending on the wage rate chosen to
value caregiving time. Different valuation methods have been
proposed, including the market wage rate, proxy wage rate, and
willingness to pay method.50,51 Depending on the wage rate, then,
opportunity costs may be over- or underestimated.50
Financial Support
Only 4 studies included assessments of financial support,
indicating a need for further research. Given that financial support
(similar to the income substitutes discussed above) may mitigate
the effects of illness-related costs, an assessment is critical to
financial burden measurement. We observed little agreement
regarding the reporting of this variable. Our experience supports
findings by Roser et al9. In their systematic review, different types
and extent of financial support precluded an overall synthesis.
Categorizing financial support according to designated use (eg,
assistance with out-of-pocket medical or nonmedical expenses)
and source may increase reporting transparency.
Considerations Regarding Methodological Approaches
Our inclusion of both longitudinal and cross-sectional studies
explains some of the heterogeneity regarding reviewed studies’
methodological approaches. Nevertheless, even in studies with
similar designs, we found little consensus in terms of recall pe-
riods, data collection modes, or data aggregation. Previous studies
noted that these methodological inconsistencies constitute a
major challenge for syntheses of research findings and cross-study
comparisons.9-11 For instance, variations in recall periods, with
longer periods increasing the risk of recall errors,52,53 render the
accuracy of cost estimates somewhat uncertain. Therefore, shorter
recall periods (eg, 1 month) yielding more precise cost estimates
are recommended.54
Additionally, cost estimates may vary depending on the data
collection mode employed. Comparing diaries and surveys, for
example, it has been suggested that cost diaries are more suitable
for smaller,more frequentexpenses, reducing recall errors,whereas
surveys are thought to bemore reliable for capturing extraordinary,
infrequent expenses.52 Nevertheless, for families living with a child
suffering from an LLC, keeping a cost diary could represent an un-
necessary burden during an already difficult time. Tsimicalis
et al37,38 kept data collection periods short by combining interview
surveys with one 1-week cost diary a month for 3 consecutive
months. Validation of self-report data, for example, against official
tax records (income loss) or receipts (out-of-pocket expenses),
should also be considered to address recall errors.
We observed high variability both in the number of cost items
(eg, gasoline, parking tickets, road tolls) aggregated within an
indicator (eg, transportation) and in the overall number of
included indicators aggregated to determine total out-of-pocket
medical and nonmedical expenses. Previous research suggeststhat aggregated totals increase with increases in the number of
measured items or indicators, increasing estimates’ accuracy and
reliability.52,54 Therefore, using multiple indicators and cost items
(as proposed in Table 5) might provide more precise estimates of
financial burden.
Strengths and Limitations
Using a scoping review methodology, we identified a wide
variety of articles on illness-related costs incurred by families of
childrenwith LLCs. The scoping reviewmethodology allowed us to
include studies of various designs, thereby providing an ideal basis
for mapping, consolidating, and disseminating evidence on
existing cost indicators and outcome measures. Nevertheless, we
did not analyze and synthesize the extent to which specific
expenses or employment disruptions contribute to families’
financial burden. This limited our conclusion about their true
monetary impact. Determining the relevance of each indicator and
outcome measure within specific contexts and settings will
require further research.Conclusions
In addition to the physical and emotional challenges of caring
for a child with an LLC, parents of these children face serious
ongoing financial consequences. To facilitate evidence-based pol-
icy interventions that reduce the burden of illness-related costs,
consistent and precise estimates of financial burden are necessary.
Based on our findings, we recommend that future cost-of-illness
studies cover all 3 relevant financial categories: direct costs, in-
direct costs, and financial support. To help standardize this task,
we generated a framework for measuring out-of-pocket expenses
providing guidance for quantifying the full direct costs borne by
families of children with LLCs. Moreover, overcoming in-
consistencies regarding outcome measures and methodological
approaches including recall periods, data collection modes, and
data aggregation methods will strengthen inter-study compari-
sons and promote the development and implementation of
effective support policies.Supplemental Material
Supplementary data associated with this article can be found in the
online version at https://doi.org/10.1016/j.jval.2021.03.015.Article and Author Information
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